1 August 2012 in Pediatrics
BACKGROUND AND OBJECTIVE: Using light-emitting diodes during conventional phototherapy, it is possible to reduce the distance from light source to infant, thus increasing light irradiance. The objective of this study was to search for a “saturation point” (ie, an irradiation level above which there is no further decrease in total serum bilirubin [TsB]). This was a prospective randomized study performed in the NICU of Aalborg Hospital, Denmark.METHODS: One hundred fifty-one infants (gestational age ≥33 weeks) with uncomplicated hyperbilirubinemia were randomized to 1 of 4 distances from the phototherapy device to the mattress (20, 29, 38, and 47 cm). TsB was measured before and after 24 hours of phototherapy and irradiance every eighth hour. Main outcome was 24-hour decrease of TsB expressed in percent, (∆ TsB0–24, difference between TsB0 and TsB24 [%]).RESULTS: A highly significant linear relation was seen between light irradiance and ∆ TsB0–24 (%) (P < .001): when the irradiance increased from 20 to 55 μW/cm2/nm, ∆ TsB0–24 (%) increased from approximately 30% to 50%. In addition, smooth regression showed no tendency for ∆ TsB0–24 (%) to level off as irradiance increased. ∆ TsB0–24 (%) was negatively correlated to birth weight and positively to formula volume. Average weight gain during phototherapy was 1%, independent of light irradiance.CONCLUSIONS: By using light-emitting diodes, we found a linear relation between light irradiance in the range of 20 to 55 μW/cm2/nm and a decrease in TsB after 24 hours of therapy, with no evidence of a saturation point.
29 October 2014 in Developmental Medicine & Child Neurology
Aim: To investigate whether infants with neonatal hyperbilirubinaemia but without intermediate or advanced bilirubin encephalopathy develop long‐term sequelae, with impairment of motor development, executive function, or hearing.Method: This nested double‐cohort study included 167 exposed children (107 males, 60 females) born in Denmark 2000 to 2005 at gestational age ≥35 weeks with a total serum bilirubin ≥450 μmol/L (26.3mg/dL) and 163 age‐, sex‐, and gestational age‐matched unexposed children (103 males, 60 females). The children were examined at a mean age of 7.7 years (SD 1.7y) using the Movement Assessment Battery for Children–Second Edition (MABC‐2), pure tone audiometry, and the Behavioural Regulation Inventory of Executive Function (BRIEF) questionnaire.Results: The follow‐up rate was 70% of the eligible infants in the exposed group and 45% in the unexposed group. Mean difference was −0.2 (95% confidence interval [CI] −1.1 to 0.8) in adjusted standard score for MABC‐2 and 0.3 (95% CI −2.9 to 3.5) in adjusted BRIEF executive composite standard score. No children had significant hearing impairment or a diagnosis of cerebral palsy, attention‐deficit–hyperactive disorder, or autism spectrum disorder recorded in national registries.Interpretation: No evidence was found of an increased risk of deficits in motor development, executive function, or hearing in children with extreme hyperbilirubinaemia who did not have intermediate or advanced bilirubin encephalopathy.
1 July 2012 in Pediatrics
OBJECTIVE: To study if severe hyperbilirubinemia in infants with no or minor neurologic symptoms in the neonatal period affects children’s development at the age of 1 to 5 years.METHODS: Controlled descriptive follow-up study of a national cohort of Danish children. The exposed group consisted of all live-born infants in Denmark from 2004 to 2007 with a gestational age ≥35 weeks and severe hyperbilirubinemia in the neonatal period, defined as at least 1 measure of total serum bilirubin level ≥25 mg/dL during the first 3 weeks of life. The exposed group of 206 children was matched with a control group of 208 children. The Ages and Stages Questionnaire (ASQ), a method of evaluating the child’s development, was filled in by parents. Main outcome measure was effect size of ASQ total score. Statistical analyses comprised a matched analysis of 102 pairs and a nonmatched regression analysis of all participants.RESULTS: The response rate was 79% (n = 162 of 206) in the study group and 70% (n = 146 of 208) in the control group. Neither the matched nor the nonmatched analysis showed any statistically significant differences between the groups; the effect size of the total score was 0.04 (−0.24 to 0.32) and −0.04 (−0.26 to 0.19), respectively.CONCLUSIONS: Using the parent-completed ASQ, we found no evidence of developmental delay in children aged between 1 and 5 years with severe neonatal hyperbilirubinemia compared with a matched control group.
1 November 2010 in Pediatric Research